Galectin-3 and fibulin-1 in systolic heart failure: relation to glucose metabolism and left ventricular contractile reserve
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Galectin-3 and fibulin-1 in systolic heart failure : relation to glucose metabolism and left ventricular contractile reserve. / Holmager, Pernille; Egstrup, Michael; Gustafsson, Ida; Schou, Morten; Dahl, Jordi S.; Rasmussen, Lars Melholt; Møller, Jacob E.; Tuxen, Christian; Faber, Jens; Kistorp, Caroline.
In: BMC Cardiovascular Disorders, Vol. 17, 22, 10.01.2017.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Galectin-3 and fibulin-1 in systolic heart failure
T2 - relation to glucose metabolism and left ventricular contractile reserve
AU - Holmager, Pernille
AU - Egstrup, Michael
AU - Gustafsson, Ida
AU - Schou, Morten
AU - Dahl, Jordi S.
AU - Rasmussen, Lars Melholt
AU - Møller, Jacob E.
AU - Tuxen, Christian
AU - Faber, Jens
AU - Kistorp, Caroline
PY - 2017/1/10
Y1 - 2017/1/10
N2 - Background: Heart failure (HF) patients with diabetes (DM) have an adverse prognosis and reduced functional capacity, which could be associated with cardiac fibrosis, increased chamber stiffness and reduced left ventricular (LV) contractile reserve. Galectin-3 (Gal-3) and fibulin-1 are circulating biomarkers potentially reflecting cardiac fibrosis. We hypothesize that plasma levels of Gal-3 and fibulin-1 are elevated in HF patients with DM and are associated with reduced LV contractile reserve in these patients. Methods: A total of 155 patients with HF with reduced ejection fraction underwent a low-dose dobutamine echocardiography and blood sampling for biomarker measurements. Patients were classified according to history of DM and an oral glucose tolerance test (OGTT) as: normal glucose tolerance (NGT) (n = 70), impaired glucose tolerance (IGT) (n = 25) and DM (n = 60). Results: Galectin-3 levels were elevated in DM patients as compared to non-diabetic patients (P = 0.02), while higher fibulin-1 levels were observed in HF patients with IGF and DM (P = 0.07). Reduced LV contractile reserve was associated with increasing Gal-3 levels (β = -0.19, P = 0.03) although, this association was attenuated after adjustment for estimated glomerular filtration rate (P = 0.66). Fibulin-1 was not associated with LV contractile reserve (P = 0.71). Conclusions: Galectin-3 and fibulin-1 levels were elevated in HF patients with impaired glucose metabolism. However, reduced LV contractile reserve among HF patients with DM does not to have an independent impact on plasma Gal-3 and fibulin-1 levels.
AB - Background: Heart failure (HF) patients with diabetes (DM) have an adverse prognosis and reduced functional capacity, which could be associated with cardiac fibrosis, increased chamber stiffness and reduced left ventricular (LV) contractile reserve. Galectin-3 (Gal-3) and fibulin-1 are circulating biomarkers potentially reflecting cardiac fibrosis. We hypothesize that plasma levels of Gal-3 and fibulin-1 are elevated in HF patients with DM and are associated with reduced LV contractile reserve in these patients. Methods: A total of 155 patients with HF with reduced ejection fraction underwent a low-dose dobutamine echocardiography and blood sampling for biomarker measurements. Patients were classified according to history of DM and an oral glucose tolerance test (OGTT) as: normal glucose tolerance (NGT) (n = 70), impaired glucose tolerance (IGT) (n = 25) and DM (n = 60). Results: Galectin-3 levels were elevated in DM patients as compared to non-diabetic patients (P = 0.02), while higher fibulin-1 levels were observed in HF patients with IGF and DM (P = 0.07). Reduced LV contractile reserve was associated with increasing Gal-3 levels (β = -0.19, P = 0.03) although, this association was attenuated after adjustment for estimated glomerular filtration rate (P = 0.66). Fibulin-1 was not associated with LV contractile reserve (P = 0.71). Conclusions: Galectin-3 and fibulin-1 levels were elevated in HF patients with impaired glucose metabolism. However, reduced LV contractile reserve among HF patients with DM does not to have an independent impact on plasma Gal-3 and fibulin-1 levels.
KW - Diabetes
KW - Fibulin-1
KW - Galectin-3
KW - Left ventricular contractile reserve
KW - Myocardial fibrosis
U2 - 10.1186/s12872-016-0437-6
DO - 10.1186/s12872-016-0437-6
M3 - Journal article
C2 - 28068900
AN - SCOPUS:85008507504
VL - 17
JO - B M C Cardiovascular Disorders
JF - B M C Cardiovascular Disorders
SN - 1471-2261
M1 - 22
ER -
ID: 189700895